EFFECT OF PERINDOPRIL ON THE QUALITY OF LIFE WITH COMORBIDITY OF OBESITY AND CORONARY HEART DISEASE

Людмила Валентиновна Васильева, В. Г остева, А.В. Никитин, S. V. Zhemchuzhikov, L. Vasilieva, E. Gosteva
{"title":"EFFECT OF PERINDOPRIL ON THE QUALITY OF LIFE WITH COMORBIDITY OF OBESITY AND CORONARY HEART DISEASE","authors":"Людмила Валентиновна Васильева, В. Г остева, А.В. Никитин, S. V. Zhemchuzhikov, L. Vasilieva, E. Gosteva","doi":"10.18413/2075-4728-2019-42-3-263-272","DOIUrl":null,"url":null,"abstract":"Currently, the increasing social importance of studying the quality of life of persons with obesity, in accordance with the national clinical guidelines for the diagnosis, treatment, prevention of obesity and associated diseases, the social importance of studying the quality of life. The aim of the work is to increase the effectiveness of treatment of patients with obesity and coronary heart disease (CHD) by including perindopril in therapy. Material. An open randomized study to improve the effectiveness of treatment of 84 patients with coronary heart disease in combination with obesity I-II art., of which 45 women and 39 men, the average age was (56,2 ± 4,8) years. Results. The patients were randomized into groups: the first 42 patients received perindopril in the complex therapy at a dose of 10 mg per day for 6 months, the second standard drug therapy. We used the Russian version of the SF-36 questionnaire. As a result of complex therapy in group 1, there was a significant (p < 0,05) increase in НАУЧНЫЕ ВЕДОМОСТИ | | Серия: Медицина. Фармация. 2019. Том 42, No 3 263 264 НАУЧНЫЕ ВЕДОМОСТИ М Н Серия: Медицина. Фармация. 2019. Том 42, No 3 quality of life on five studied scales of the SF-36 questionnaire (General Health -by 16 points, 40 %; Vitality by 15,9 points, 48 %; Physical Functioning by 29,5 points, 85 %; Sosial Functioning 10,2 points, 20 %; Role-Physical 17,8 points, 45 %), the indicator of the pain intensity scale significantly decreased (Body Pain by 24 score, 48 %). In group 2, there was also an improvement in all indicators of quality of life, which did not reach the degree of reliability, a significant (p < 0,05) decrease by 35 % of the pain intensity index (17,4 points). Conclusion. An effective method of treatment of patients with CHD and obesity is the inclusion of perindopril 10 mg/day in this cohort of patients. Ключевые слова: ишемическая болезнь сердца, ожирение, качество жизни, периндоприл.","PeriodicalId":8785,"journal":{"name":"Belgorod State University Scientific bulletin Medicine Pharmacy","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Belgorod State University Scientific bulletin Medicine Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18413/2075-4728-2019-42-3-263-272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Currently, the increasing social importance of studying the quality of life of persons with obesity, in accordance with the national clinical guidelines for the diagnosis, treatment, prevention of obesity and associated diseases, the social importance of studying the quality of life. The aim of the work is to increase the effectiveness of treatment of patients with obesity and coronary heart disease (CHD) by including perindopril in therapy. Material. An open randomized study to improve the effectiveness of treatment of 84 patients with coronary heart disease in combination with obesity I-II art., of which 45 women and 39 men, the average age was (56,2 ± 4,8) years. Results. The patients were randomized into groups: the first 42 patients received perindopril in the complex therapy at a dose of 10 mg per day for 6 months, the second standard drug therapy. We used the Russian version of the SF-36 questionnaire. As a result of complex therapy in group 1, there was a significant (p < 0,05) increase in НАУЧНЫЕ ВЕДОМОСТИ | | Серия: Медицина. Фармация. 2019. Том 42, No 3 263 264 НАУЧНЫЕ ВЕДОМОСТИ М Н Серия: Медицина. Фармация. 2019. Том 42, No 3 quality of life on five studied scales of the SF-36 questionnaire (General Health -by 16 points, 40 %; Vitality by 15,9 points, 48 %; Physical Functioning by 29,5 points, 85 %; Sosial Functioning 10,2 points, 20 %; Role-Physical 17,8 points, 45 %), the indicator of the pain intensity scale significantly decreased (Body Pain by 24 score, 48 %). In group 2, there was also an improvement in all indicators of quality of life, which did not reach the degree of reliability, a significant (p < 0,05) decrease by 35 % of the pain intensity index (17,4 points). Conclusion. An effective method of treatment of patients with CHD and obesity is the inclusion of perindopril 10 mg/day in this cohort of patients. Ключевые слова: ишемическая болезнь сердца, ожирение, качество жизни, периндоприл.
培哚普利对肥胖合并冠心病患者生活质量的影响
目前,研究肥胖症患者的生活质量的社会重要性日益增加,根据国家肥胖症及相关疾病的诊断、治疗、预防临床指南,研究生活质量的社会重要性日益增加。这项工作的目的是通过在治疗中加入培哚普利来提高治疗肥胖和冠心病(CHD)患者的有效性。材料。一项开放的随机研究,以提高84例冠心病合并肥胖患者的治疗效果。其中女性45例,男性39例,平均年龄(56,2±4,8)岁。结果。患者被随机分组:前42例患者接受培哚普利复合治疗,剂量为10mg /天,持续6个月,第二次标准药物治疗。我们使用的是俄文版的SF-36问卷。第一组患者综合治疗后,НАУЧНЫЕ ВЕДОМОСТИ | | Серия: Медицина显著增高(p < 0.05)。Фармация。2019. Том42,没有3 263 264НАУЧНЫЕВЕДОМОСТИМНСерия:Медицина。Фармация。2019. Том 42、在SF-36调查问卷(一般健康)的五个研究尺度上,生活质量排名第三——提高16分,40%;活力下降15.9分,48%;身体机能提高29.5分,85%;社会功能10,2分,20%;角色-身体17分,8分,45%),疼痛强度量表指标显著降低(身体疼痛24分,48%)。第二组患者的生活质量各项指标均有改善,但均未达到信度,疼痛强度指数下降35% (p < 0.05)(17.4分)。结论。治疗冠心病和肥胖患者的一种有效方法是在该队列患者中纳入培哚普利10mg /天。Ключевыеслова:ишемическаяболезньсердца,ожирение,качествожизни,периндоприл。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信